Faculty
Gustave Roussy Cancer Center, Université Paris-Saclay, INSERM U1015
Villejuif, Ile-de-France, France
Dr. Birgit Geoerger is pediatric oncologist heading the Pediatric Early Drug Development Program in the Department of Pediatric and Adolescent Oncology at Gustave Roussy Cancer Center in Villejuif, France. Dr. Geoerger is recognized for her expertise in childhood cancer new drug development and is heading the INCa labeled early phase clinical trial center in pediatric hemato-oncology (CLIP²-2015-2024), which regroups Gustave Roussy, Robert Debré and Trousseau Hospitals.
Within the precision cancer medicine efforts, she has initiated the MAPPYACTS molecular profiling trial and the AcSé-ESMART molecularly guided therapeutic platform trial, both sponsored by Gustave Roussy, and is coordinating the pediatric relapse indication of the France Medécine Génomique 2025 program and the MAPPYACTS 2 study. She had developed and contributed to multiple early clinical, first-in-child and first-in-class trials.
Her laboratory group “Precision Medicine and Experimental Therapeutics” in the INSERM U1015 research laboratory of Prof Laurence Zitvogel aims at developing new therapies for pediatric cancers through the identification of new therapeutic targets in the cancer precision medicine program. Potential targets and their role in oncogenesis or resistance are explored in relevant pre-clinical models.
She is member of the AACR, ASCO, SFCE, SIOPE and SIOP; was chair of the Clinical Trials during 11 years, member of the Biology and the Executive Committee of the European Innovate Therapies for Children with Cancer (ITCC) consortium, member of multiple scientific committees, editorial boards and advisory boards. She is Section Editor for Pediatric Oncology of the European Journal of Cancer since February 2023 and Faculty Member of the MCCR Methods in Clinical Research Workshop since 2012. In 2006 she received the Gustave Roussy Award from the Chancelleries des Universités de Paris, Sorbonne. Dr Geoerger has authored more than 150 peer-reviewed publications referenced in Medline.
Disclosure information not submitted.
Paper 51 - TUMOR CELL PLASTICITY DEFINE OSTEOSARCOMA SUBTYPES
Friday, November 3, 2023
2:30 PM – 4:00 PM